Top Markets
#1 Akedo Akedo +59.31%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.07%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.55%
#6 τemplar τemplar +26.67%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.66%
#8 Bitway Bitway +18.26%
#9 Perle Perle +16.48%
#10 Cap Cap +16.47%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Clasificación en acciones #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Precio por acción
$0.41
Última sincronización: 2025-01-23
Capitalización bursátil
$1.08M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio CohBar, Inc. (CWBR)

Categoría

Healthcare
Ratio P/B de CohBar, Inc. (CWBR)
Ratio P/B al August 2026 TTM: 0.08
Según los informes financieros más recientes y el precio de las acciones de CohBar, Inc., el ratio P/B actual (TTM) es 0.08. Al final de 2021, el ratio P/B era 0.91.
Historial del ratio P/B de CohBar, Inc. desde 2011 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2026 (TTM) 0.08 -75.78%
2022 0.32 -64.70%
2021 0.91 -74.27%
2020 3.54 -57.97%
2019 8.42 17.87%
2018 7.14 -70.78%
2017 24.44 213.13%
2016 7.81 115.36%
2015 3.62 -84.35%
2014 23.15 -103.81%
2013 -607.96 -3,077.68%
2012 20.42 0.00%
2011 0.00 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 7,979.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 8,091.35%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 4,589.03%
BE